SCD News Hub
Zydus gets orphan drug status for Sickle Cell Disease medication
Zydus Lifesciences receives Orphan Drug Designation for Desidustat, a new treatment for Sickle Cell Disease.
Read moreZydus’ Desidustat gets Orphan Drug Designation from U.S. FDA for Sickle Cell disease
Zydus on Friday said U.S. Food and Drug Administration has granted Orphan Drug Designation (ODD) to Desidustat for the treatment of Sickle Cell Disease (SCD).
Read moreMarquette players have a 10-year-old teammate. It's a sweet story.
B.J. Mathews loves basketball and is dealing with sickle cell disease. That brought him into the orbit of the Golden Eagles.
Read moreZydus’ Desidustat gets USFDA orphan drug status for sickle cell disease
Zydus Lifesciences announced a significant development today. The US Food and Drugs Administration has granted Orphan Drug Designation to Desidustat. This novel oral medication is intended for the treatment of Sickle Cell Disease. This designation supports the development of therapies for rare diseases. Zydus believes Desidustat can address an urgent medical need for patients.
Read moreZydus Life bags USFDA orphan drug tag for Desidustat indicated for sickle cell disease treatment
The company noted that current treatment options for SCD are limited, while hydroxyurea can reduce the frequency of painful crises.
Read moreZydus gets orphan drug status for Sickle Cell Disease medication
Zydus gets orphan drug status for Sickle Cell Disease medication
Read moreZydus Lifesciences Receives USFDA Orphan Drug Designation for Sickle Cell Disease Treatment
Zydus Lifesciences has received USFDA orphan drug designation for Desidustat in treating sickle cell disease, marking a significant regulatory milestone. This status could grant the company seven-year exclusive marketing rights upon approval, providing substantial commercial advantages. The designation validates Desidustat's potential in addressing sickle cell disease and positions Zydus strategically in the rare disease therapeutic market.
Read moreYoung adults with complex childhood conditions experience longer hospital stays, higher readmissions
Young adults with complex chronic childhood-onset conditions such as sickle cell disease and cystic fibrosis experience longer hospital stays, higher readmission rates and greater use of resources in adult hospitals, according to a new study in JAMA Network Open.
Read moreStudy finds longer hospital stays and higher readmissions for young adults with complex childhood conditions
More children with medically complex conditions are surviving into adulthood, but researchers have had limited visibility into how these conditions influence adult hospital care. Young adults with complex chronic childhood-onset conditions such as sickle cell disease and cystic fibrosis experience longer hospital stays, higher readmission rates, and greater use of resources in adult hospitals, according to a new study.
Read moreFury as NHS trust closes 'vital' London emergency unit for those with deadly disorder
Sickle Cell Disease is the fastest-growing blood disorder
Read more